The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Successful Islet Transplantation
Open accessAbstract
Clinical islet transplantation is gaining acceptance as a potential therapy, particularly for subjects who have labile diabetes or problems with hypoglycemic awareness. The risks of the procedure and long-term outcomes are still not fully known. We have performed 54 islet transplantation procedures on 30 subjects and have detailed follow-up in 17 consecutive Edmonton protocol-treated subjects who attained insulin independence after transplantation of adequate numbers of islets. Subjects were assessed pretransplant and followed prospectively posttransplant for immediate and long-term complications related to the procedure or immunosuppressive therapy. The 17 patients all became insulin independent after a minimum of 9,000 islets/kg were transplanted. Of 15 consecutive patients with at least 1 year of follow-up after the initial transplant, 12 (80%) were insulin independent at 1 year. In 14 subjects who have maintained demonstrable C-peptide secretion, glucose control has been stable and glycemic lability and problems with hypoglycemic reactions have been corrected. After 2 of the 54 procedures, some thrombosis was detected in the portal vein circulation. Five subjects had bleeding related to the percutaneous portal vein access procedures: three required transfusion alone, and in one subject, who had a partial thrombosis of the portal vein, an expanding intrahepatic and subscapular hemorrhage occurred while on anticoagulation, requiring transfusion and surgery. Elevated liver function test results were found in 46% of subjects but resolved in all. Complications related to the therapy have been hypercholesterolemia requiring statin therapy in 65%; a rise in creatinine in two patients, both of whom had preexisting renal disease; a rise in protein in four, all of whom had preexisting proteinuria; and antihypertensive therapy increased or started in 53%. Three of the 17 patients have required retinal laser photocoagulation. There have been no cases of posttransplant lymphoproliferative disorder or cytomegalovirus infection, and no deaths. The acute insulin response to arginine correlated better with transplanted islet mass than acute insulin response to glucose (AIRg) and area under the curve for insulin (AUCi), but the AIRg and AUCi were more closely related to glycemic control. The AUCi directly posttransplant was lower in those who eventually became C-peptide deficient. Our results, with a maximum follow-up of 34 months, indicate that prolonged insulin independence can be achieved after islet transplantation. There are some risks associated acutely with the procedure, and hypercholesterolemia and hypertension are treatable concerns on longer-term follow-up. All patients with persisting C-peptide secretion have had a resolution of both glycemic lability and problems with hypoglycemic reactions. Apart from the rise in serum creatinine in two subjects, no serious consequences of immunosuppressive therapy have been encountered. Islet transplantation is a reasonable option in those with severe problems with glycemic lability or hypoglycemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Assuming a similar dose as with human islets from deceased donors,175,176 on the order of 109 cells will be required per patient.”
From Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes (2023) · cites this paper as [176]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shapiro, A. M. J., Lakey, J. R. T., Ryan, E. A., Korbutt, G. S., Toth, E., Warnock, G. L., Kneteman, N. M., & Rajotte, R. V. (2000) · New England Journal of Medicine · doi:10.1056/nejm200007273430401 · Cited by 5,237
Self-citationCorrect Homeostasis Model Assessment (HOMA) Evaluation Uses the Computer Program
Lévy, J., Matthews, D. R., & Hermans, M. P. (1998) · Diabetes Care · doi:10.2337/diacare.21.12.2191 · Cited by 2,023
Mean Amplitude of Glycemic Excursions, a Measure of Diabetic Instability
Service, F. J., Molnar, G. D., Rosevear, J. W., Ackerman, E., Gatewood, L. C., & Taylor, W. F. (1970) · Diabetes · doi:10.2337/diab.19.9.644 · Cited by 1,039
Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol.
Ryan, E., Lakey, J., Rajotte, R., Korbutt, G., Kin, T., Imes, S., Rabinovitch, A., Elliott, J., Bigam, D., Kneteman, N., et al. (2001) · Diabetes · doi:10.2337/diabetes.50.4.710 · Cited by 875
Self-citationIslet isolation assessment in man and large animals
Ricordi, C., Gray, D. W. R., Hering, B. J., Kaufman, D. B., Warnock, G. L., Kneteman, N. M., Lake, S. P., London, N. J. M., Socci, C., Alejandro, R., et al. (1990) · Acta Diabetologica · doi:10.1007/bf02581331 · Cited by 577
Self-citationNephrotoxicity of immunosuppressive drugs: Long-term consequences and challenges for the future
de Mattos, A. M., Olyaei, A. J., & Wm, B. (2000) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(00)70348-9 · Cited by 429
Automated Islet Isolation From Human Pancreas
Ricordi, C., Lacy, P. E., & Scharp, D. W. (1989) · Diabetes · doi:10.2337/diab.38.1.s140 · Cited by 386
EFFECT OF 1 YEAR OF NEAR-NORMAL BLOOD GLUCOSE LEVELS ON RETINOPATHY IN INSULIN-DEPENDENT DIABETICS
Lauritzen, T., Larsen, H., Frost-Larsen, K., Deckert, T., & The Steno Study Group (1983) · The Lancet · doi:10.1016/s0140-6736(83)92585-0 · Cited by 372
Dahl-Jørgensen, K., Brinchmann-Hansen, O., Hanssen, K. F., Sandvik, L., & Aagenaes, O. (1985) · BMJ · doi:10.1136/bmj.290.6471.811 · Cited by 360
Drachenberg, C. B., Klassen, D. K., Weir, M. R., Wiland, A., Fink, J. C., Bartlett, S. T., Cangro, C. B., Blahut, S. A., & Papadimitriou, J. C. (1999) · Transplantation · doi:10.1097/00007890-199908150-00012 · Cited by 342
Research works printed but not linked: 1
- Korc M: Normal function of the endocrine pancreas. In The Pancreas. Go VLW, Dimagno EP, Gardner JD, Lebenthal E, Reber HA, Scheele GA, Eds. New York, Raven Press, 1993, p.751–758
Cited by
Sorted by citations
Items 701–719 of 719
Liu, Z., Pei, G., Cai, X., Zou, J., Ding, X., Sun, P., Liang, R., Zhang, B., & Wang, S. (2023) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000128
Mahoney, A. L. G., Joshua, S., Nassif, N. T., & Simpson, A. M. (2023) · International Journal of Translational Medicine · doi:10.3390/ijtm3030026
Insulin protein abundance matters in human pancreatic islets homeostasis
Vion, J., & Bouzakri, K. (2023) · Acta Physiologica · doi:10.1111/apha.14076
Genetic Safety Switches for Pluripotent Stem Cell-Derived Therapies for Diabetes
Cohen, D. E., & Odorico, J. S. (2023) · Springer eBooks · doi:10.1007/978-3-031-41943-0_17
Considerations Pertaining to Implant Sites for Cell-Based Insulin Replacement Therapies
Marfil‐Garza, B. A., Cuesta‐Gomez, N., & Shapiro, A. M. J. (2023) · Springer eBooks · doi:10.1007/978-3-031-41943-0_16 · Cited by 1
Self-citationMizui, T., Inagaki, A., Nakamura, Y., Imura, T., Uematsu, S. S., Miyagi, S., Kamei, T., Unno, M., Watanabe, K., & Goto, M. (2024) · Cells · doi:10.3390/cells13060499
Teo, A. K. S., Tan, K. S. M., Koh, Y. X., Koh, A., & Teo, A. K. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-824465-4.00143-5
Plasma cortisol levels are associated with the first-phase insulin secretion in type 2 diabetesPreprint
Wang, K., Luo, X., Zheng, S., Zhou, J., Li, S., Chen, H., & Chen, N. (2025) · Research Square · doi:10.21203/rs.3.rs-7245624/v1
Kato, H., Sigdel, T. K., Sheta, M., Omori, K., Qi, M., KANDEEL, F. R., & Komatsu, H. (2025) · Cell Transplantation · doi:10.1177/09636897251390960
Novel Approaches to Immunosuppression in Liver Transplantation
Toso, C., Mason, A. L., & Kneteman, N. M. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-028-1_2
Self-citationHematopoietic Stem Cell Transplant in the Treatment of Autoimmune Endocrine Disease
Schumacher, J., & Carrier, E. (2005) · Humana Press eBooks · doi:10.1385/1-59259-900-1:221
Danne, T., Freckmann, G., Kautzky‐Willer, A., Lang, U. E., Lehmann, R., Pfohl, M., Schloot, N. C., & Schumm‐Draeger, P. (2014) · Springer eBooks · doi:10.1007/978-3-642-41358-2_3
Hiscox, A. (2008) · UA Campus Repository (The University of Arizona)
Role of Islet Endothelial Cells in β-cell Function and Growth
Johansson, M. (2006) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
The Deubiquitinating Enzyme Otub2 Modulates Pancreatic Beta-Cells Function and Survival
Oshry, M., Isaac, R., Boura‐Halfon, S., Casana, E., Sampson, S. R., Lev, S., Bosch, F., Zick, Y., & Vinik, Y. (2026) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl44406
Rao, J. S., Guo, Z., Khashim, Z., Knofczynski, K. R., Tobolt, D. K., Shivakumar, S. B., Rangarajan, P., Herman, A., Abdulla, M., Tran, A., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.25.720819
Bellini, M. I., & Papalois, V. E. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15176774
HYPOXIA INDUCES DYSFUNCTION AND CELL DEATH OF THE RAT PANCREATIC ISLET
Tomotsune, K., Ogawa, Y., Hasegawa, N., Kudo, T., Naraoka, M., Chikazawa, S., Tamasawa, N., & Suda, T. (2009) · 弘前醫學
Codario, R. A. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-469-8_9
Metadata
- Authors
- Ryan, E. A., Lakey, J. R. T., Paty, B. W., Imes, S., Korbutt, G. S., Kneteman, N. M., Bigam, D., Rajotte, R. V., & Shapiro, A. M. J.
- Affiliations
- University of Alberta (CA)
- Capital Health Authority, Edmonton, Alberta, Canada
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2002-07-01
- Volume
- 51
- Issue
- 7
- Pages
- 2148-2157
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2102915416
- Cited by
- 719
- References
- 35
- Citations by year
- 2026: 3 · 2025: 10 · 2024: 7 · 2023: 10 · 2022: 10 · 2021: 10 · 2020: 12 · 2019: 15 · 2018: 22 · 2017: 12 · 2016: 15 · 2015: 16 · 2014: 27 · 2013: 17 · 2012: 27
- FWCI
- 77.16
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Juvenile Diabetes Research Foundation International
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- islet transplantation, type 1 diabetes, insulin independence, Edmonton protocol, C-peptide, glycemic control, hypoglycemia, portal vein thrombosis, immunosuppression complications, post-transplant complications, acute insulin response, islet mass, retinal photocoagulation, long-term outcomes, hypercholesterolemia, liver function tests, post-transplant lymphoproliferative disorder
- MeSH terms
- Insulin Secretion, Adult, Blood Glucose, C-Peptide, Female, Follow-Up Studies, Glucose Tolerance Test, Glycated Hemoglobin, Humans, Insulin, Male, Portal Vein, Postoperative Complications, Time Factors, Islets of Langerhans Transplantation, Treatment Outcome, Age of Onset
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
